NCT05603598 (LEAP2-OBCT) is a NA clinical trial of LEAP-2 Protein, Human in Obesity, sponsored by University Hospital, Gentofte, Copenhagen.

Who is sponsoring NCT05603598?

NCT05603598 is sponsored by University Hospital, Gentofte, Copenhagen.

What drugs are being tested in NCT05603598?

Interventions in NCT05603598: LEAP-2 Protein, Human.

Is NCT05603598 still recruiting?

NCT05603598 is currently status unknown. Last updated 2 November 2022.

Last reviewed 2022-11-02 · How we verify

NCT05603598: LEAP2-OBCT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

LEAP2 on Postprandial Glucose Metabolism and Food Intake n Obese Males

Status unknown NA Last updated 2 November 2022

What this trial tests

NA trial testing LEAP-2 Protein, Human in Obesity in 20 participants. Status unknown.

Timeline

24 August 2022

Primary endpoint
1 May 2023

1 May 2023

Quick facts

Lead sponsor	University Hospital, Gentofte, Copenhagen
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	basic science
Enrollment	20
Start date	24 August 2022
Primary completion	1 May 2023
Estimated completion	1 May 2023
Sites	1 location across Denmark

Drugs / interventions tested

LEAP-2 Protein, Human — full drug profile →

Conditions studied

Obesity — all drugs for Obesity →

Sponsor

University Hospital, Gentofte, Copenhagen

Who can join

Adults 18 to 60, male only, with Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aims to delineate the effects of the naturally occurring peptide liver-enriched antimicrobial peptide 2 (LEAP-2) on postprandial glucose metabolism and food intake in obese volunteers. The overall objective is to investigate the physiological importance of LEAP-2 in obese subjects.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Current and emerging strategies to curb antibiotic-resistant urinary tract infections.
Simoni A, Schwartz L, Junquera GY, Ching CB, et al · · 2024 · cited 28× · PMID 38714857 · DOI 10.1038/s41585-024-00877-9
Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy.
Nicze M, Dec A, Borówka M, Krzyżak D, et al · · 2024 · cited 9× · PMID 39125772 · DOI 10.3390/ijms25158202
LEAP2 Reduces Ad Libitum Food Intake and Attenuates Postprandial Glucose Excursions in Men With Obesity.
Englund A, Lange AH, Hagemann CA, Kizilkaya HS, et al · · 2026 · PMID 41911360 · DOI 10.2337/db25-1132

Verify or expand the search:

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Other University Hospital, Gentofte, Copenhagen trials

Trials by the same sponsor.

NCT07171723 — Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment · Phase 1, PHASE2 · recruiting
NCT06934473 — Effects of Endogenous GIP on Postprandial Blood Pressure in Healthy Individuals · NA · recruiting
NCT06845033 — Effects of Antagonizing the Ghrelin Receptor on Brain Food Cue Reactivity in Obesity · NA · not yet recruiting
NCT06787001 — Understanding How Gut and Brain Barriers Are Linked to Inflammation in Obesity · completed
NCT06881459 — The Effect of Oxytocin on the Alpha Cell Response to Hypoglycaemia in Patients With Type 1 Diabetes · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05603598 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Gentofte, Copenhagen
Last refreshed: 2 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05603598.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing